dsur-workbench

Case cards

The six fictional programs used throughout the book, one printable card each (US Letter, one to two pages). Each card reproduces the case from Appendix D (history, trials, reference safety information, the safety events that shape its DSURs, what it tests) and lists the chapters, sections, figures and exercises that use it.

Item Format What it is for Book reference
case-A-ONK-417.docx Word Case A: ONK-417, oral kinase inhibitor, solid tumors. First-in-human program across DSURs 1 to 3: the first DSUR with little data, actions taken, and an evolving Summary of Important Risks Appendix D, Case A; Chapters 1, 2, 6–9, 11–13, 16; Figures 9.3, 11.1
case-B-XB-7.docx Word Case B: XB-7, monoclonal antibody, autoimmune disease. Blinded Phase 3 program, DSUR 5: exposure without unblinding, a mid-period IB change adding sepsis, Section 18, late-breaking information, QC and executive review Appendix D, Case B; Chapters 1–6, 8–13, 15, 17; basis of worked-example/
case-C-CX-3.docx Word Case C: CX-3, marketed oral anticoagulant, new indication. DSUR and PBRER side by side and synchronization, marketing experience, regional overlays, a regulator question Appendix D, Case C; Chapters 1, 2, 4, 5, 7, 8, 11, 14–16; Figures 14.2, 15.3, 16.2
case-D-VD-12.docx Word Case D: VD-12, adjuvanted vaccine, healthy adults. Low event rates against background incidence, adverse events of special interest, endpoint exclusions Appendix D, Case D; Chapters 1, 5, 6, 9 (Exercise 1), 10, 12, 13; Figures 5.3, 10.4
case-E-GT-5.docx Word Case E: GT-5, AAV gene therapy, rare neuromuscular disease. Tiny denominators, delayed and theoretical risks, long-term follow-up, the final-DSUR statement Appendix D, Case E; Chapters 1, 5, 9, 11, 12 (Exercise 1), 13, 16
case-F-PX-22.docx Word Case F: PX-22, small molecule, co-developed. Separate DSURs with a partner, data gaps, divergent RSI, Section 14 Appendix D, Case F; Chapters 1, 2, 4, 5, 7, 12, 17

Fictional data only; not regulatory advice. Licensed under CC BY-NC 4.0; commercial use needs a corporate license.